Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

DNA vaccines: an active immunization strategy for prostate cancer.

Wolchok JD, Gregor PD, Nordquist LT, Slovin SF, Scher HI.

Semin Oncol. 2003 Oct;30(5):659-66. Review.

PMID:
14571413
2.

Tumor vaccines for the management of prostate cancer.

McNeel DG, Disis ML.

Arch Immunol Ther Exp (Warsz). 2000;48(2):85-93. Review.

PMID:
10807048
3.

Immunotherapy for prostate cancer.

Fong L, Small EJ.

Semin Oncol. 2003 Oct;30(5):649-58. Review.

PMID:
14571412
4.

Advances in specific immunotherapy for prostate cancer.

Kiessling A, Füssel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, Schmitz M.

Eur Urol. 2008 Apr;53(4):694-708. Epub 2007 Nov 26. Review.

PMID:
18061335
5.

Prostate-specific membrane antigen: current and future utility.

Gregorakis AK, Holmes EH, Murphy GP.

Semin Urol Oncol. 1998 Feb;16(1):2-12. Review.

PMID:
9508077
6.

[Cell therapy and prostate cancer].

Eymard JC, Bernard J.

Bull Cancer. 2003 Aug-Sep;90(8-9):734-43. Review. French.

7.

Prostate-specific membrane antigen vaccines: naked DNA and protein approaches.

Slovin SF.

Clin Prostate Cancer. 2005 Sep;4(2):118-23. Review.

PMID:
16197613
8.

Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.

Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ.

Semin Oncol. 2003 Oct;30(5):667-76. Review.

PMID:
14571414
9.

Targeted therapies for prostate cancer against the prostate specific membrane antigen.

Elsässer-Beile U, Bühler P, Wolf P.

Curr Drug Targets. 2009 Feb;10(2):118-25. Review.

PMID:
19199907
10.

Progress in active specific immunotherapy of prostate cancer.

Tjoa BA, Murphy GP.

Semin Surg Oncol. 2000 Jan-Feb;18(1):80-7. Review.

PMID:
10617899
11.

The potential of DNA vaccination against tumor-associated antigens for antitumor therapy.

Haupt K, Roggendorf M, Mann K.

Exp Biol Med (Maywood). 2002 Apr;227(4):227-37. Review.

PMID:
11910045
12.

[Novel vaccines against M. tuberculosis].

Okada M.

Kekkaku. 2006 Dec;81(12):745-51. Review. Japanese.

PMID:
17240920
13.

Prostate cancer: advances in immunotherapy.

Hurwitz AA, Yanover P, Markowitz M, Allison JP, Kwon ED.

BioDrugs. 2003;17(2):131-8. Review.

PMID:
12641491
14.

DNA vaccines for the treatment of prostate cancer.

Alam S, McNeel DG.

Expert Rev Vaccines. 2010 Jul;9(7):731-45. doi: 10.1586/erv.10.64. Review.

PMID:
20624047
15.

CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.

Lubaroff DM, Karan D.

Adv Drug Deliv Rev. 2009 Mar 28;61(3):268-74. doi: 10.1016/j.addr.2008.12.005. Epub 2009 Jan 7. Review.

PMID:
19166887
16.

Prostate cancer vaccines: maximizing a suboptimal immune response for improved outcome.

Slovin SF.

Clin Adv Hematol Oncol. 2007 Dec;5(12):972-80. Review.

PMID:
18277959
17.

Developing dendritic cell polynucleotide vaccination for prostate cancer immunotherapy.

Berlyn KA, Ponniah S, Stass SA, Malone JG, Hamlin-Green G, Lim JK, Cottler-Fox M, Tricot G, Alexander RB, Mann DL, Malone RW.

J Biotechnol. 1999 Aug 20;73(2-3):155-79. Review.

PMID:
10486925
18.

[Updated application of prostate-specific membrane antigen to the diagnosis and treatment of prostate cancer].

Tang QL, Yao MY.

Zhonghua Nan Ke Xue. 2008 Jan;14(1):79-82. Review. Chinese.

PMID:
18297820
19.

Pox viral vaccine approaches.

Arlen PM, Kaufman HL, DiPaola RS.

Semin Oncol. 2005 Dec;32(6):549-55. Review.

PMID:
16338420
20.

Immunologic targeting: how to channel a minimal response for maximal outcome.

Slovin SF.

Curr Opin Urol. 2006 May;16(3):179-85. Review.

PMID:
16679856

Supplemental Content

Support Center